Silencing UBQLN2 Enhances the Radiosensitivity of Esophageal Squamous Cell Carcinoma (ESCC) via Activating p38 MAPK

Figure 1

The prognostic role of UBQLN2 in patients with esophageal squamous cell carcinoma (ESCC). (a) A box and bar graph comparing the levels of UBQLN2 mRNA between ESCC and normal paracancerous tissues.  < 0.01 of Student's t-test. (b) Nomogram model predicting the 1-year overall survival (OS) of patients with ESCC. The high expression of UBQLN2 contributed nearly 100 points, which was higher than that of age and pTNM staging. (c) Kaplan–Meier analysis of OS in ESCC patients with the different expression levels of UBQLN2 mRNA in cancer tissue. Data from The Cancer Genomic Atlas (TCGA). (d) Negative (top) and positive (bottom) immunohistochemical (IHC) staining of UBQLN2 in ESCC tissues of our own cohort. Kaplan–Meier analysis demonstrated that the expression level of UBQLN2 had no effect on the survival of patients with ESCC in our own cohort ( = 0.6398). However, in ESCC patients with lymph node metastasis, the OS of patients with low expression of UBQLN2 was significantly better than that of patients with high expression of UBQLN2 ( = 0.0018).

(a)

(b)

(c)

(d)